Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus VANOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus VANOS.
ARAZLO vs VANOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
VANOS (fluocinonide 0.1% cream) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2 and reduction of prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin layer to affected areas once or twice daily. Not for use longer than 2 weeks; maximum 15 g per day.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
The terminal elimination half-life is approximately 7.5 hours (range 5-12 hours). This supports twice-daily or once-daily dosing for sustained local effect.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal excretion (glucuronidation and sulfation); minimal biliary elimination (<5%). Approximately 60-70% of the dose is excreted in urine as metabolites, with <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid